Navigation Links
Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
Date:2/22/2013

NEW YORK, Feb. 22, 2013 /PRNewswire/ -- Dr Wei William Cao, PhD, BM, President of Cellular Biomedicine Group presented a keynote address at the 8th annual New York Stem Cell Summit on February 19, 2013. Dr Cao discussed the current government regulations and support of cellular medicine research and development in China.

The New York Stem Cell Summit featured more than 30 of the world's leaders in the stem cell industry, bringing the future of this dynamic industry to life for investors, industry, practitioners, and analysts. The presentations and networking provided insight into investment opportunities in the stem cell marketplace, groundbreaking stem cell products that physicians use today, and the growing market potential.

Dr Cao served as Technical Manager for Bayer Diagnostics Asia Pacific region, General Manager of GenoMultix Ltd., President of Wuxi New District Hospital, and China General Manager of Affymetrix, a world leader in genetic analysis industry. Dr Cao has extensive research experience in immunopharmacology at Harvard Medical School and Stanford Medical School.  He holds a Guest Professorship at the Department of Histology and Embryology of Fudan University Medical School, Shanghai China. Dr Cao earned a Bachelor's degree in Medicine from Fudan University Medical School, Shanghai China, and PhD degree in immunopharmacology from Medical College of Virginia, Richmond Virginia. He is an inventor of 24 patents in the field of genetic analysis and stem cell technology, especially adipose derived stem cell preparation and its disease treatment applications.

About Cellular Biomedicine Group
Cellular Biomedicine Group, Ltd. develops proprietary cell therapies for the treatment of certain degenerative diseases. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company has no obligation to update these forward-looking statements.

CONTACT:

Jeff Ramson
Investor Relations
ProActive Capital Group
646-863-6341

Sarah Kelly
Director of Corporate Communications
(+86) 21 54069990 
sarah.kelly@cellbiomedgroup.com

 



 

 

 


'/>"/>
SOURCE Cellular Biomedicine Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
2. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
3. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
4. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
5. Proteins shine a brighter light on cellular processes
6. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
7. Cellular Dynamics Announces Commercial Launch of iCell® Neurons for Neuroscience Drug Discovery
8. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
9. A 300 Million Euro Boost for Biomedicine in Berlin
10. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
11. Photonics21 Group Announces Prize for Photonics with Industrial Impact
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):